The ECS and Runner's High: The Revised Science

The Myth You Were Taught in Gym Class

Maybe you have finished a long run, a hard ride, or a brutal swim and felt a wave of calm euphoria wash over you. You were probably told the same story everyone gets told: endorphins. That floaty, blissed-out feeling is supposedly your brain flooding with natural opioids. It is one of the most repeated claims in fitness culture. It is printed on posters, quoted by coaches, and baked into the very phrase “endorphin rush.”

There is just one problem. The endorphin explanation is almost certainly wrong. At the very least, it is badly incomplete.

Over the past two decades, a quiet revolution in neuroscience has pointed to a different culprit: your endocannabinoid system. That is the same biological network cannabis acts on. The molecules behind the runner’s high appear to be your body’s own cannabis-like compounds. In other words, you may already know what a runner’s high feels like. It is your brain producing a gentle, homegrown version of the effects that THC borrows.

Let me walk you through how the science got revised, what the landmark studies showed, and how all of this relates to (and differs from) consuming cannabis. To set the stage, it helps to understand the system itself, which I cover in the endocannabinoid system guide.

What the Runner’s High Actually Is

Before we assign blame, let’s define the suspect. Researchers describe the runner’s high as a cluster of four distinct sensations that can appear during or shortly after sustained aerobic exercise:

• Euphoria — a pleasant, mildly elevated mood
• Anxiolysis — a reduction in anxiety and worry
• Analgesia — a blunting of pain sensitivity
• Sedation — a calm, settled, sometimes sleepy feeling afterward

Crucially, these are not guaranteed. The runner’s high is famously elusive. Plenty of dedicated athletes rarely feel it, while others get it reliably. As you will see, the intensity and duration of exercise matter enormously—and so, probably, does your individual biology.

That variability is itself a clue. If a single flood of endorphins produced the effect, you might expect it to be more consistent. The reality is messier, and the messiness points toward a more nuanced signaling system.

The Endorphin Story—and Why It Falls Apart

The endorphin hypothesis was born in the 1980s, when scientists noticed that blood levels of beta-endorphin (an opioid peptide) rise after vigorous exercise. The logic seemed airtight: opioids elevate mood and dull pain, endorphins are opioids, and they spike when you run. Case closed.

Except for one stubborn anatomical fact.

Beta-endorphin is a fairly large peptide molecule. And it cannot cross the blood–brain barrier. That barrier is the tightly controlled border that decides which molecules in your bloodstream reach your brain. Researcher Johannes Fuss, who led much of the key work, put it plainly: the team turned to the endocannabinoid system because “endorphins can’t pass through the blood-brain barrier.” That makes it unlikely that endorphins in your blood are producing a feeling inside your head.

So yes, you can measure more beta-endorphin in the blood after a workout. But blood is not the brain. The classic test that should have settled this gives athletes naloxone, a drug that blocks opioid receptors. Over the years, the results have been inconsistent. If endorphins were the whole story, blocking opioid receptors should reliably erase the runner’s high. It does not. I dig deeper into this border-control problem in the blood-brain barrier and cannabis.

This is where the endocannabinoids enter—because, unlike endorphins, they sail right across that barrier.

Enter the Endocannabinoids

Your body produces its own cannabinoids, called endocannabinoids. The two best-studied are anandamide (AEA)—nicknamed the “bliss molecule”—and 2-arachidonoylglycerol (2-AG). These are fatty, lipid-based molecules. That chemistry appears to matter: because they are lipophilic (fat-loving), researchers note they can readily cross the blood–brain barrier that stops endorphins cold [Raichlen et al., 2012].

Anandamide is, in a very real sense, your body’s homegrown answer to THC. It binds to the same CB1 and CB2 receptors that cannabis compounds do. If you want the full origin story of this remarkable molecule, I wrote a dedicated piece on anandamide, your body’s natural THC, and a companion guide on how 2-AG controls dopamine decisions. The difference in CB1 receptor location—central versus peripheral—turns out to be central to the runner’s high story, which is why understanding CB1 vs CB2 receptors is so useful here.

Here is the elegant part: exercise raises your endocannabinoid levels, those molecules can actually reach your brain, and they act on the very system that produces calm, mood elevation, and pain relief. The pieces fit in a way the endorphin story never quite did.

The Landmark Study: Fuss et al., 2015

The study that reframed the field was published in the Proceedings of the National Academy of Sciences in 2015 by Johannes Fuss and colleagues at the University of Heidelberg [Fuss et al., 2015]. It did something the older human studies could not. It used the precision of mouse genetics to ask which signaling system is actually responsible.

Here is how the team did it. They let mice run on wheels, then compared runners against sedentary controls using two well-validated tests: a dark–light box to measure anxiety (anxious mice hide in the dark; relaxed mice explore the light) and a hot plate test to measure pain sensitivity.

The runners came back calmer and more pain-tolerant—a rodent runner’s high. And blood measurements confirmed that running elevated endocannabinoids, with anandamide rising significantly (P = 0.03).

Then came the clever part. The researchers blocked each candidate system in turn:

• Naloxone (blocking opioids/endorphins): the runner’s calm and pain relief persisted. Endorphins were not necessary.
• AM251 (blocking central CB1 receptors): the anxiety reduction vanished. Cannabinoid signaling was necessary.
• AM6545 and AM630 (blocking peripheral CB1 and CB2 receptors): the pain relief vanished.

To nail it down, they used mice genetically engineered to lack CB1 receptors specifically on forebrain GABAergic neurons. In those animals, running produced no anxiety reduction at all. The conclusion, in the authors’ words, was that “the endocannabinoid system is crucial for two main aspects of a runner’s high”—reduced anxiety via central CB1 receptors, and reduced pain via peripheral CB1 and CB2 receptors.

One honest caveat the authors themselves raised: euphoria, the most famous feature of the runner’s high, simply cannot be measured in a mouse. So the 2015 study rigorously demonstrated the anxiolysis and analgesia mechanisms, while leaving the euphoria question for human research.

What the Human Studies Show

Mice are not people, so what does the human evidence say? It is suggestive but not yet conclusive—and I want to be straight with you about that.

The first human study to connect the dots came from Sparling and colleagues in 2003, who found that 45 minutes of moderate running or cycling significantly raised plasma anandamide in trained volunteers [Sparling et al., 2003]. A decade later, David Raichlen’s team ran an evolutionary twist. They compared humans, dogs (natural distance runners), and ferrets (which are not). Both humans and dogs showed anandamide spikes after high-intensity treadmill running, while ferrets showed nothing. In humans, the rise in anandamide tracked closely with better self-reported mood [Raichlen et al., 2012].

A follow-up from the same group found something practical. The endocannabinoid response is intensity-dependent [Raichlen et al., 2013]. Anandamide rose meaningfully at roughly 70–85% of maximum heart rate. It did not rise during gentle walking, and it did not rise during all-out sprinting. There seems to be a sweet spot—a “Goldilocks zone” of moderate-to-vigorous effort—where the system switches on.

A 2024 outdoor-running study went further. It measured both anandamide and 2-AG before and after a 60-minute run. Mood, AEA, and 2-AG all rose significantly afterward (p<0.0001 for mood and AEA, p<0.01 for 2-AG), with some interesting differences by sex and running frequency [Desch et al., 2024].

But here is the most important human finding, and it deserves emphasis. In 2021, Fuss’s group tested the opioid hypothesis directly in people: they gave runners naloxone to block endorphins. The exercise-induced euphoria and anxiety reduction happened anyway [Siebers et al., 2021]. Just as in mice, blocking opioids did not abolish the runner’s high in humans.

A 2022 systematic review by the same lab summed up the state of play honestly [Siebers et al., 2022]. Across 21 qualifying clinical trials, 14 of 17 acute-exercise studies found endocannabinoids rising afterward. Those increases were repeatedly associated with features of the runner’s high. Yet the authors stopped short of declaring victory. They noted that “reliable proof of the involvement of eCBs in the runner’s high in humans has not yet been achieved due to methodological hurdles.” Correlation in humans, causation in mice—that is the current frontier.

Why This Matters Beyond Running

Step back and the implications get genuinely interesting. If exercise reliably nudges your endocannabinoid system, then movement is, in a loose sense, a way of gently engaging the same machinery cannabis engages—endogenously, on your own terms, with your body in full control of the dose.

This dovetails with a broader idea I find compelling: the concept of endocannabinoid tone, the baseline level of activity in your ECS. Some researchers theorize that chronically low tone may contribute to certain mood and pain conditions, an idea explored in work on clinical endocannabinoid deficiency. Regular aerobic exercise may be one of the most accessible, side-effect-free ways to support healthy endocannabinoid signaling—though I want to be careful: this is a plausible mechanism, not a prescription, and exercise’s benefits are vast and overlapping. The ECS is one thread in a much larger tapestry, as the broader endocannabinoid tone theory discusses.

It also reframes how we think about exercise and mood. The well-documented antidepressant and anti-anxiety effects of regular movement may run partly through this cannabinoid pathway—a connection that overlaps with research on cannabis and serotonin and the way the ECS modulates dopamine and your stress hormone cortisol.

How Cannabis Relates—and How It Differs

Now for the question every cannabis reader is asking: if exercise activates the endocannabinoid system, and cannabis activates the endocannabinoid system, are they the same thing?

No. And the distinction is important.

The runner’s high is your body releasing its own endocannabinoids—anandamide and 2-AG—in modest, self-regulated amounts that your enzymes clear away within minutes to hours. THC, by contrast, is an external cannabinoid that floods CB1 receptors far more powerfully and lingers far longer, because your body does not break it down the way it breaks down anandamide. That is precisely why a cannabis high is more intense and more prolonged than a runner’s high. Same receptors, very different dose and duration.

This is also why the popular shorthand “cannabis gives you a runner’s high in a gummy” is misleading. They share a target, not an experience.

Where things get genuinely interesting is the intersection: combining cannabis with exercise. A growing number of athletes use cannabis for recovery and to make training more enjoyable, a topic I explore in cannabis for athletic recovery. If you are curious which chemovars athletes gravitate toward, see the best cannabis strains for working out and exercise and the data on cannabis and VO2max. For the broader endurance angle, cannabis and hiking covers how some people stack movement and cannabinoids deliberately. Just remember: the science on cannabis enhancing performance is far thinner than the science on the endogenous runner’s high, and effects vary wildly between people—which is exactly why I always come back to understanding your own ideal high rather than chasing a label.

The Limitations (Because Honest Science Has Them)

I would be doing you a disservice if I dressed this up as settled fact. Here is what we genuinely do not know yet:

• The strongest causal evidence is in mice, not humans. The 2015 knockout-and-blocker experiments are elegant, but you cannot ethically delete receptors from people. Human studies remain largely correlational.
• Euphoria is hard to study. It cannot be measured in animals, and self-report in humans is notoriously noisy.
• 2-AG’s role is inconsistent. Several studies find anandamide rising reliably while 2-AG does not, or vice versa. The full molecular choreography is unresolved.
• Individual variation is huge. Genetics, fitness level, fasted state, and exercise intensity all shift the response, which is part of why not everyone gets a runner’s high.
• None of this is medical advice. Exercise may support endocannabinoid signaling, but if you have a health condition, the right move is a conversation with a clinician—not a blog post, even a well-cited one.

The honest summary: the endocannabinoid system is very likely a major driver of the runner’s high, the old endorphin story is at best incomplete, and the human causal proof is still being assembled.

FAQ

Is the runner’s high the same as being high on cannabis? No. Both engage your endocannabinoid receptors, but the runner’s high comes from your body’s own anandamide and 2-AG in small, short-lived amounts. Cannabis delivers external THC that hits those receptors far harder and lasts much longer.

Do endorphins play any role at all? Possibly a minor one, but the evidence that they cause the classic mood-and-pain effects is weak. Endorphins can’t cross the blood–brain barrier, and blocking opioid receptors with naloxone fails to abolish the runner’s high in both mice and humans.

What kind of exercise triggers it? Moderate-to-vigorous aerobic exercise—roughly 70–85% of your maximum heart rate—appears to be the sweet spot. Gentle walking and all-out sprinting don’t reliably raise endocannabinoids in the studies done so far.

Does this mean exercise can replace cannabis? They’re different tools. Exercise is a fantastic, side-effect-free way to support your endocannabinoid system, but it produces a milder, briefer effect than cannabis. Many people use both for different reasons.

Can I feel a runner’s high from cycling or swimming? Likely yes. The research has documented endocannabinoid increases from running and cycling, and the mechanism isn’t specific to running—it’s tied to sustained aerobic intensity.

Key Takeaways

The runner’s high is one of the best illustrations of why I keep harping on the endocannabinoid system. It is not a niche cannabis topic. It is a regulatory network you carry everywhere, switching on when you move, eat, sleep, and yes, when you consume cannabis. The endorphin myth persisted for decades because it was a tidy story. The revised science is messier and more humbling, but far more interesting. The same system cannabis borrows is one your own body fires up every time you push hard enough.

To boil it down:

• The classic “endorphin rush” explanation is, at best, incomplete.
• Your own endocannabinoids—anandamide and 2-AG—are the leading candidates, and they cross the blood–brain barrier that blocks endorphins.
• The strongest causal proof is in mice; human evidence is suggestive but still correlational.
• Moderate-to-vigorous aerobic effort (~70–85% of max heart rate) is the likely sweet spot.
• The runner’s high shares receptors with cannabis, but it is not the same experience—your own dose is smaller and shorter.

Understanding that connection won’t make your next long run easier. But it might make it feel a little more profound. And it should make you think harder about how you, specifically, respond to anything that touches this system. That, as always, is the whole point of knowing exactly why you’re high.

Sources

• Fuss, J., Steinle, J., Bindila, L., et al. (2015). A runner’s high depends on cannabinoid receptors in mice. Proceedings of the National Academy of Sciences, 112(42), 13105–13108. DOI: 10.1073/pnas.1514996112
• Raichlen, D. A., Foster, A. D., Gerdeman, G. L., Seillier, A., & Giuffrida, A. (2012). Wired to run: exercise-induced endocannabinoid signaling in humans and cursorial mammals with implications for the ‘runner’s high’. Journal of Experimental Biology, 215(8), 1331–1336. DOI: 10.1242/jeb.063677
• Raichlen, D. A., Foster, A. D., Seillier, A., Giuffrida, A., & Gerdeman, G. L. (2013). Exercise-induced endocannabinoid signaling is modulated by intensity. European Journal of Applied Physiology, 113(4), 869–875. DOI: 10.1007/s00421-012-2495-5
• Sparling, P. B., Giuffrida, A., Piomelli, D., Rosskopf, L., & Dietrich, A. (2003). Exercise activates the endocannabinoid system. NeuroReport, 14(17), 2209–2211. DOI: 10.1097/00001756-200312020-00015
• Siebers, M., Biedermann, S. V., Bindila, L., Lutz, B., & Fuss, J. (2021). Exercise-induced euphoria and anxiolysis do not depend on endogenous opioids in humans. Psychoneuroendocrinology, 126, 105173. DOI: 10.1016/j.psyneuen.2021.105173
• Siebers, M., Biedermann, S. V., & Fuss, J. (2022). Do Endocannabinoids Cause the Runner’s High? Evidence and Open Questions. The Neuroscientist, 29(3), 352–369. DOI: 10.1177/10738584211069981
• Desch, S., et al. (2024). Investigating Runner’s High: Changes in Mood and Endocannabinoid Concentrations after a 60 min Outdoor Run. Sports, 12(9), 232. DOI: 10.3390/sports12090232